论文部分内容阅读
目的观察中药联合序贯维持性腹膜透析治疗慢性肾功能衰竭患者的临床疗效及对血清转化生长因子β1(TGF-β1)的影响。方法选择2012年1月—2015年8月收治的50例维持性腹膜透析患者,随机分为对照组和治疗组各25例。两组均给予CAPD腹膜透析方案治疗,对照组给予西医常规治疗,治疗组在此基础上给予中药辨证治疗,疗程4周。检测患者Scr、Hb、BUN、TGF-β1水平,并进行证候评分比较。计量资料组间比较采用t检验,组内比较采用配对t检验,P<0.05为差异有统计学意义。结果治疗组治疗后血Scr、Hb、BUN、TGF-β1水平分别为(268.4±58.8)μmol/L、(91.34±3.11)g/L、(15.70±3.87)mmol/L、(0.89±0.27)ng/ml,均较治疗前的(431.8±77.6)μmol/L、(79.59±2.05)g/L、(22.05±5.06)mmol/L、(2.82±1.54)ng/ml明显改善,差异均有统计学意义(均P<0.05)。治疗后,治疗组Scr、Hb、BUN、TGF-β1水平均优于对照组[(401.7±60.5)μmol/L、(81.10±2.07)g/L、(18.13±3.43)mmol/L、(2.03±1.51)ng/ml],差异均有统计学意义(均P<0.05)。结论中药治疗可显著改善维持性腹膜透析患者的中医症状,有效提高Hb、降低BUN、TGF-β1,延缓肾纤维化趋势。
Objective To observe the clinical efficacy and the effect of serum transforming growth factor-β1 (TGF-β1) in patients with chronic renal failure treated with traditional Chinese medicine combined with sequential maintenance peritoneal dialysis. Methods Fifty patients with maintenance peritoneal dialysis who were admitted from January 2012 to August 2015 were randomly divided into control group and treatment group of 25 cases. Both groups were given CAPD peritoneal dialysis program treatment, the control group given Western conventional treatment, the treatment group on this basis to give Chinese medicine treatment, treatment for 4 weeks. The level of Scr, Hb, BUN and TGF-β1 in the patients were detected and the scores of syndromes were compared. Measurement data were compared between groups using t test, the group was compared using paired t test, P <0.05 for the difference was statistically significant. Results The levels of Scr, Hb, BUN and TGF-β1 in the treatment group after treatment were (268.4 ± 58.8) μmol / L, 91.34 ± 3.11 and 15.70 ± 3.87 mmol / L, (431.8 ± 77.6) μmol / L, (79.59 ± 2.05) g / L, (22.05 ± 5.06) mmol / L and (2.82 ± 1.54) ng / ml before treatment were significantly higher than those before treatment Statistical significance (all P <0.05). After treatment, the levels of Scr, Hb, BUN and TGF-β1 in the treatment group were significantly higher than those in the control group [(401.7 ± 60.5) μmol / L, (81.10 ± 2.07) g / L, ± 1.51) ng / ml], the differences were statistically significant (all P <0.05). Conclusion Chinese medicine treatment can significantly improve the traditional Chinese medicine in patients with maintenance peritoneal dialysis, effectively improve Hb, reduce BUN, TGF-β1, delay the trend of renal fibrosis.